Atlas Trials

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Clinical trial NCT06773312 · RECRUITING

Trial details

NCT number
NCT06773312
Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Start date
2025-02-28
Primary completion
2026-10-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.